Tenaya Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Tenaya Therapeutics's estimated annual revenue is currently $20.9M per year.
- Tenaya Therapeutics's estimated revenue per employee is $139,500
- Tenaya Therapeutics's total funding is $248M.
- Tenaya Therapeutics's current valuation is $412.8M. (January 2022)
Employee Data
- Tenaya Therapeutics has 150 Employees.
- Tenaya Therapeutics grew their employee count by 15% last year.
Tenaya Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP People and Culture | Reveal Email/Phone |
2 | SVP, Portfolio and Program Management | Reveal Email/Phone |
3 | VP, Clinical Development | Reveal Email/Phone |
4 | SVP, Regulatory | Reveal Email/Phone |
5 | Senior Director, Accounting Operations | Reveal Email/Phone |
6 | Chief Financial and Business Officer | Reveal Email/Phone |
7 | Senior Director Clinical Operations | Reveal Email/Phone |
8 | Senior Director, Clinical Development | Reveal Email/Phone |
9 | Manager, Process Development | Reveal Email/Phone |
10 | Senior Manager, Translation Medicine | Reveal Email/Phone |
Tenaya Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Tenaya Therapeutics?
Tenaya Therapeutics is a privately-held biopharmaceutical company backed by The Column Group. The Company was founded in 2016 by world-leading scientists from the Gladstone Institute's Cardiovascular Division and the University of Texas Southwestern Medical Center. Tenaya is dedicated to addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration. Tenaya has a lead gene therapy program focused on in vivo reprogramming of cardiac fibroblasts to cardiomyocytes to regenerate heart tissue, and additional programs focused on cardiomyopathies.
keywords:N/A
$248M
Total Funding
150
Number of Employees
$20.9M
Revenue (est)
15%
Employee Growth %
$412.8M
Valuation
N/A
Accelerator
Tenaya Therapeutics News
(WVE), Century Therapeutics (IPSC), Achilles Therapeutics plc (ACHL), Taysha Gene Therapies (TSHA), Passage Bio (PASG) and Tenaya Therapeutics (...
... cellular reprogramming, purging damaged cells and plasma-derived therapies. ... including Tenaya Therapeutics in South San Francisco;...
--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver potentially...
Tenaya Therapeutics has raised a $106 million Series C led by RTW Investments. The Bay Area company is developing therapies to address cardiovascular disease, with a focus on gene therapy, cellular regeneration and precision medicine. Tenaya raised $92 million at a $210 million valuation in 2019 ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $66.2M | 150 | -4% | $345.4M |
#2 | $36.5M | 151 | 56% | N/A |
#3 | $30.2M | 156 | 12% | $381M |
#4 | $10M | 164 | 37% | $207.4M |
#5 | $23.7M | 166 | 11% | $125M |